Jamjoom Pharma 2025 profit rises 30% to SAR 463.8M; Q4 at SAR 68.1M
View other reports
Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) reported a net profit of SAR 463.8 million in 2025, an increase of 30% compared to SAR 356.5 million a year earlier.
Financials (M)
| Item | 2024 | 2025 | Change |
|---|---|---|---|
| Revenues | 1,318.48 | 1,500.60 | 13.8 % |
| Gross Income | 820.50 | 938.80 | 14.4 % |
| Operating Income | 381.10 | 474.80 | 24.6 % |
| Net Income | 356.52 | 463.80 | 30.1 % |
| Average Shares | 70.00 | 70.00 | - |
| Earnings Per Share before unusual items (Riyals) | 5.09 | 6.63 | 30.1 % |
| EPS (Riyal) | 5.09 | 6.63 | 30.1 % |
This was driven by higher revenue, improved gross margins from favorable product mix, and strong operating leverage. Earnings were additionally backed by positive net finance income and profit contributions from the Algerian joint venture, alongside lower ECL provisions and the absence of prior-year one-off charges.
Current Quarter Comparison (M)
| Item | Q4 2024 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 259.70 | 304.55 | 17.3 % |
| Gross Income | 158.51 | 186.62 | 17.7 % |
| Operating Income | 54.02 | 71.35 | 32.1 % |
| Net Income | 51.61 | 68.07 | 31.9 % |
| Average Shares | 70.00 | 70.00 | - |
| Earnings Per Share before unusual items (Riyal) | 0.74 | 0.97 | 31.9 % |
| EPS (Riyal) | 0.74 | 0.97 | 31.9 % |
Q4 2025 profit jumped 32% to SAR 68.1 million, compared to SAR 51.61 million in the prior-year period.
On a sequential basis, net profit dropped by 36.2% from SAR 106.67 million in Q3 2025.
Total shareholders’ equity (no minority interest) amounted to SAR 1.71 billion as of Dec. 31, 2025, compared to SAR 1.49 billion in a year earlier period.
Financial results (Million)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| Q1 2025 | 457.53 | 18.7 % | 292.85 | 17.4 % | 156.96 | 24.0 % |
| Q2 2025 | 396.22 | 14.6 % | 250.80 | 14.9 % | 133.39 | 27.9 % |
| Q3 2025 | 342.31 | 4.5 % | 208.54 | 7.3 % | 108.08 | 13.0 % |
| Q4 2025 | 304.55 | 17.3 % | 186.62 | 17.7 % | 71.35 | 32.1 % |
| 2025 | 1,500.60 | 13.8 % | 938.80 | 14.4 % | 474.80 | 24.6 % |
Profit Performance (Million)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS(Riyal) |
|---|---|---|---|---|---|---|
| Q1 2025 | 157.03 | 52.5 % | 2.24 | - | 157.03 | 2.24 |
| Q2 2025 | 132.02 | 23.4 % | 1.89 | - | 132.02 | 1.89 |
| Q3 2025 | 106.67 | 12.3 % | 1.52 | - | 106.67 | 1.52 |
| Q4 2025 | 68.07 | 31.9 % | 0.97 | - | 68.07 | 0.97 |
| 2025 | 463.80 | 30.1 % | 6.63 | - | 463.80 | 6.63 |
Profitability
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2024 | 63.57 % | 31.55 % | 26.12 % |
| Q2 2024 | 62.76 % | 31.56 % | 26.80 % |
| Q3 2024 | 61.60 % | 31.80 % | 27.56 % |
| Q4 2024 | 62.23 % | 31.70 % | 27.04 % |
| 2024 | 62.23 % | 31.74 % | 27.04 % |
| Q1 2025 | 62.13 % | 32.43 % | 29.53 % |
| Q2 2025 | 62.22 % | 33.38 % | 30.23 % |
| Q3 2025 | 62.56 % | 34.00 % | 30.73 % |
| Q4 2025 | 62.56 % | - | 30.91 % |
| 2025 | 62.56 % | - | 30.91 % |
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2025 | 70.00 | 5.87 | 5.87 | 22.09 |
| Q2 2025 | 70.00 | 6.22 | 6.22 | 24.03 |
| Q3 2025 | 70.00 | 6.39 | 6.39 | 23.61 |
| Q4 2025 | 70.00 | 6.63 | 6.63 | 24.53 |
Multiple Ratios (End of Period Price)
| Period | P/E | Recurring P/E | Price/book |
|---|---|---|---|
| Q1 2025 | 26.60 | 26.60 | 7.06 |
| Q2 2025 | 27.83 | 27.83 | 7.21 |
| Q3 2025 | 24.66 | 24.66 | 6.68 |
| Q4 2025 | 21.48 | 21.48 | 5.80 |
Business Segments (Million)
Q3 2025
| Period | Pharmaceutical products | Consumer Health Products |
|---|---|---|
| Q1 2025 | 397.88 | 59.64 |
| Q2 2025 | 340.71 | 55.52 |
| Q3 2025 | 289.84 | 52.47 |
Analysts Estimates (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Average | 72.76 | 68.07 |
Estimates vs Actual (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| SNB Capital | 64.30 | 68.07 | |
| AlJazira Capital | 72.00 | 68.07 | |
| U-Capital | 63.50 | 68.07 | |
| GIB Capital | 74.00 | 68.07 | |
| United Securities Company | 90.00 | 68.07 |
| Current | |
| Market Cap (M Riyal) | 9,450.01 |
| Enterprise Value (EV) (M Riyal) | 9,091.84 |
| Shares Outstanding ((M)) | 70.00 |
| EPS ( Riyal) (TTM) | 6.63 |
| Book Value (BV) ( Riyal) | 24.53 |
| Par Value ( Riyal) | 10.00 |
| Recurring P/E | 20.38 |
| P/E (TTM) | 20.38 |
| Price/book | 5.50 |
| Return on Average Assets (%) (TTM) | 24.3 |
| Return on Average Equity (%) (TTM) | 28.9 |
| EV/adj EBITDA | - |
| EV/Revenues | 6.06 |
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}